U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C12H14N2O2S2.2Na
Molecular Weight 328.361
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of EMERAMIDE SODIUM

SMILES

[Na+].[Na+].[S-]CCNC(=O)C1=CC(=CC=C1)C(=O)NCC[S-]

InChI

InChIKey=MCCQWWFYPPJJJP-UHFFFAOYSA-L
InChI=1S/C12H16N2O2S2.2Na/c15-11(13-4-6-17)9-2-1-3-10(8-9)12(16)14-5-7-18;;/h1-3,8,17-18H,4-7H2,(H,13,15)(H,14,16);;/q;2*+1/p-2

HIDE SMILES / InChI

Description

Emeramide or Irminix® (N,N'-bis(2-mercaptoethyl)isophthalamide (NBMI)) is a lipid-soluble thiol-redox antioxidant and heavy metal chelator. Orphan Drug Designation has been granted for the prevention and treatment of mercury toxicity in the EU and USA. Phase 1 and Phase 2a clinical studies have been performed and found Irminix® to be effective and safe with no adverse effects. A Phase 2a clinical trial for the treatment of chronic obstructive pulmonary disease has been completed in summer of 2018 and found Irminix® to be safe with no adverse effects.

CNS Activity

Originator

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
For the 14 days of the intervention 100 mg NBMI, 300 mg NBMI or placebo were administered orally to all patients.
Route of Administration: Oral